

OyaGen Presents a Novel Treatment Candidate for COVID-19

- **OyaGen, Inc is an upstate NY biotech company that has developed Oya1, a highly potent and cost effective antiviral therapeutic for COVID-19 with intended use in the treatment for patients with an active COVID-19 infection.**
- **Oya1 will address the unmet need for an effective countermeasure to fill the gaps where vaccines do not have an immediate benefit for patients who are already infected or are immune-compromised.**
- **Combined treatments of Oya1 and remdesivir or monoclonal antibodies are anticipated to markedly enhance therapeutic efficacy while mitigating the emergence of drug resistant CoV.**
 - NIH/NCI has shown Oya1 to be safe across a range of doses and dose intervals when tested in humans enrolled in prior cancer clinical trials.
 - Oya1 low nanomolar antiviral efficacy has been third party validated by NIH/NIAID.
 - Oya1 has an average selectivity index ≥ 14 when tested in different cell types.
 - Maximum tolerated doses are known for rodents, dogs and African green monkeys.
 - NIH/NIAID has shown that Oya1 blocks the virus from making copies of itself. It does so at low and high virus levels and even when added before or after the virus enters cells.
- **COVID-19 therapeutics that include Oya1 will be a game changer.**
 - Oya1 ≥ 30 -times more effective against live SARS-CoV-2 than Gilead Science's remdesivir in laboratory tests.
 - Oya1 and remdesivir have additive antiviral effects and when combined, reduce the amount of total drug necessary to kill the virus.
 - Mab require specialized lab resources for their production. They are biologics that are very expensive to produce and may require special storage conditions.
 - Oya1 has an inexpensive five step synthesis, has a long shelf-life, and does not require special considerations for storage or shipment; addressing a global demand for therapeutic options.
- **There is an immediate and long-term demand for Oya1 regardless of the availability of vaccines or monoclonal antibodies (Mab) therapies.**
 - Vaccines are not therapeutic; alone they are not indicated for reducing active COVID disease because of the time it takes to mount an immune response.
 - COVID vaccines could be given to 'sick' people in combination with potent and fast acting therapeutics such as Oya1 that do not depend on an immune response.
 - While Mab treatments are intended for treating infected patients, like vaccines, they may only be effective for the current strain of CoV (e.g. Flu vaccines).
 - Combined modality therapeutics also are required to suppress emergence of therapeutic resistant CoV strains selected by monotherapy with remdesivir or Mab.
- **Pre-IND discussions with the FDA have confirmed studies that will gate the entry of Oya1 for human Phase I clinical trials.**
- **The company seeks to partner or license Oya1 or obtain a tranching capital raise enabling OyaGen to complete remaining preclinical studies required by the FDA for approval of an IND and Phase I clinical safety and pharmacokinetic studies.**